Floatz Rating
B61/100
Confidence
Indicative
Sponsor
I-Mab Biopharma US Limited
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07432295CT.gov Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | — | Recruiting | — | — | — |
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
NCT05945823CT.gov Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05152147CT.gov A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | — | Active Not Recruiting | — | — | — |
NCT04430738CT.gov Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | — | Active Not Recruiting | — | — | — |
NCT04210115CT.gov Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluorouracilum (this asset) | I-Mab Biopharma US Limited | P3 | B · 61 |
| Capecitabine | I-Mab Biopharma US Limited | P3 | B |
| Cetuximab | BeOne Medicines | P2 | B |
| Tislelizumab | BeOne Medicines | P3 | B |
| Oxaliplatin | I-Mab Biopharma US Limited | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | B |
| Durvalumab | University of California, Irvine | P2 | B |
| Pembrolizumab | Diwakar Davar | P3 | B |
| Trastuzumab | Boehringer Ingelheim | P3 | B |
+42 more in the Esophageal Adenocarcinoma cohort
Other indications for Fluorouracilum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 77 |
| Rectal Cancer | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluorouracilum in Esophageal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluorouracilum-esophageal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →